Literature DB >> 11861840

High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses.

Karl Haglund1, Ingrid Leiner, Kristen Kerksiek, Linda Buonocore, Eric Pamer, John K Rose.   

Abstract

We investigated the primary cellular immune responses to human immunodeficiency virus type 1 (HIV-1) Env and Gag proteins elicited by recombinant vesicular stomatitis viruses (rVSVs). The primary response to Env peaked 5 to 7 days after intraperitoneal vaccination, at which time 40% of CD8(+) cells were Env tetramer positive and activated (CD62L(Lo)). These freshly isolated cells actively lysed target cells pulsed with the p18-I10 peptide and secreted gamma interferon and tumor necrosis factor alpha after stimulation with the Env p18-I10 peptide. The primary response to Env elicited by rVSVs was sixfold higher than that elicited by recombinant vaccinia viruses (rVVs) at 5 days postvaccination. An intranasal route of vaccination with VSV-Env also elicited a strong primary response to Env. The primary immune response to Gag elicited by rVSV peaked 7 days after vaccination, at which time 3% of CD8(+) cells were Gag tetramer positive and CD62L(Lo) and functional by intracellular cytokine staining. This response was eightfold higher than that elicited by rVV expressing Gag. VSV-GagEnv, which expresses both Gag and Env from a single recombinant, also induced strong cytotoxic T-lymphocyte (CTL) responses to both Env and Gag. Our quantitative analyses illustrate the potency of the VSV vector system in CTL induction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861840      PMCID: PMC136000          DOI: 10.1128/jvi.76.6.2730-2738.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Generation of mucosal cytotoxic T cells against soluble protein by tissue-specific environmental and costimulatory signals.

Authors:  S K Kim; D S Reed; S Olson; M J Schnell; J K Rose; P A Morton; L Lefrançois
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

2.  Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles.

Authors:  M J Schnell; L Buonocore; E Kretzschmar; E Johnson; J K Rose
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

3.  Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge.

Authors:  A Roberts; E Kretzschmar; A S Perkins; J Forman; R Price; L Buonocore; Y Kawaoka; J K Rose
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

4.  Attenuated vesicular stomatitis viruses as vaccine vectors.

Authors:  A Roberts; L Buonocore; R Price; J Forman; J K Rose
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

5.  Coordinate regulation of complex T cell populations responding to bacterial infection.

Authors:  D H Busch; I M Pilip; S Vijh; E G Pamer
Journal:  Immunity       Date:  1998-03       Impact factor: 31.745

Review 6.  Vaccinia virus immune evasion.

Authors:  G L Smith
Journal:  Immunol Lett       Date:  1999-01       Impact factor: 3.685

7.  Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer.

Authors:  A Seth; I Ourmanov; M J Kuroda; J E Schmitz; M W Carroll; L S Wyatt; B Moss; M A Forman; V M Hirsch; N L Letvin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

8.  A plasma membrane localization signal in the HIV-1 envelope cytoplasmic domain prevents localization at sites of vesicular stomatitis virus budding and incorporation into VSV virions.

Authors:  J E Johnson; W Rodgers; J K Rose
Journal:  Virology       Date:  1998-11-25       Impact factor: 3.616

9.  The MHC class I-restricted immune response to HIV-gag in BALB/c mice selects a single epitope that does not have a predictable MHC-binding motif and binds to Kd through interactions between a glutamine at P3 and pocket D.

Authors:  M Mata; P J Travers; Q Liu; F R Frankel; Y Paterson
Journal:  J Immunol       Date:  1998-09-15       Impact factor: 5.422

10.  Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo.

Authors:  M F Callan; L Tan; N Annels; G S Ogg; J D Wilson; C A O'Callaghan; N Steven; A J McMichael; A B Rickinson
Journal:  J Exp Med       Date:  1998-05-04       Impact factor: 14.307

View more
  38 in total

1.  Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.

Authors:  Bishnu P Nayak; Gangadhara Sailaja; Abdul M Jabbar
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 2.  Nonsegmented negative-strand viruses as vaccine vectors.

Authors:  Alexander Bukreyev; Mario H Skiadopoulos; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

3.  Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Kristin Kee; Celsa A Spina; Xiao-Fang Yu; Richard S Kornbluth
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals.

Authors:  Elizabeth Ramsburg; Jean Publicover; Linda Buonocore; Amanda Poholek; Michael Robek; Amy Palin; John K Rose
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 5.  Current prospects and future challenges for nasal vaccine delivery.

Authors:  Helmy Yusuf; Vicky Kett
Journal:  Hum Vaccin Immunother       Date:  2016-12-09       Impact factor: 3.452

Review 6.  Rhabdoviruses as vectors for vaccines and therapeutics.

Authors:  Gabrielle Scher; Matthias J Schnell
Journal:  Curr Opin Virol       Date:  2020-10-29       Impact factor: 7.090

7.  The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.

Authors:  Melissa A Cobleigh; Clinton Bradfield; Yuanjie Liu; Anand Mehta; Michael D Robek
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

8.  Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.

Authors:  James P McGettigan; Kristin Naper; Jan Orenstein; Martin Koser; Philip M McKenna; Matthias J Schnell
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 9.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

10.  Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin.

Authors:  Kazu Okuma; Kevin P Dalton; Linda Buonocore; Elizabeth Ramsburg; John K Rose
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.